Citius Oncology (CTOR) Common Equity (2022 - 2026)

Citius Oncology (CTOR) has 5 years of Common Equity data on file, last reported at $35.3 million in Q1 2026.

• On a quarterly basis, Common Equity fell 1.05% year-over-year to $35.3 million in Q1 2026; TTM through Mar 2026 was $35.3 million, a 1.05% decrease from a year earlier, with the FY2025 full-year figure at $44.9 million, down 2.76% from the prior year.
• Common Equity for Q1 2026 stood at $35.3 million, down from $58.4 million in the prior quarter.
• Over the last five years, Common Equity for CTOR reached as high as $58.4 million in Q4 2025 and fell as low as -$1968.0 in Q2 2023.
• Historically, Common Equity has averaged $27.1 million across 5 years, with a median of $29.0 million in 2023.
• Across the five-year window, Common Equity surged 865489.28% in 2024 and declined 2.76% in 2025, its largest moves.
• Year by year, Common Equity stood at $345508.0 in 2022, then surged by 6477.35% to $22.7 million in 2023, then jumped by 81.69% to $41.3 million in 2024, then jumped by 41.47% to $58.4 million in 2025, then plunged by 39.62% to $35.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $35.3 million in Q1 2026, $58.4 million in Q4 2025, and $44.9 million in Q3 2025.